Adamas Announces Publication of Amantadine Immediate Release Subgroup Analysis From EASE LID 2 Open-label Study in Movement Disorders Clinical Practice
“These data suggest that patients currently being treated with amantadine IR could be switched directly to GOCOVRI without interruption,” stated
“We continue to collect and analyze data from our EASE LID 2 open-label Phase 3 clinical trial, as we further characterize the benefits and risks of GOCOVRI,” said
The analyses were previously presented in a poster session at the
About the EASE LID 2 Open-label Study
The EASE LID 2 study is a long-term, ongoing Phase 3 open-label study of GOCOVRI for the treatment of dyskinesia patients with Parkinson’s disease. The study enrolled 223 patients from the three GOCOVRI placebo-controlled efficacy trials in Parkinson’s disease patients with dyskinesia (EASED, EASE LID and EASE LID 3), as well as Parkinson’s disease patients with dyskinesia who have undergone deep brain stimulation (DBS) treatment. Patients are being followed for up to two years. The primary objective of the study is to characterize the long-term safety and tolerability of GOCOVRI dosed once daily at bedtime for the treatment of dyskinesia in patients with Parkinson’s disease. Secondary objectives include evaluating the durability of GOCOVRI on motor complications (dyskinesia and OFF) as assessed by the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), Part IV, as well as evaluating the clinical progression of Parkinson’s disease.
GOCOVRI (amantadine) extended release capsules is the first and only medicine approved by the
About Adamas Pharmaceuticals, Inc.
Adamas is using its deep understanding of time-dependent biology to redefine the treatment experience for patients suffering from chronic neurological diseases. The company is building upon the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only
Statements contained in this press release regarding matters that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements contained in this press release regarding the potential clinical benefits of GOCOVRI or the completion of the EASE LID 2 and reporting topline findings in the second quarter of 2018 because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. For a description of risks and uncertainties that could cause actual results to differ from those expressed in forward-looking statements, including risks relating to Adamas' research, clinical, development and commercial activities relating to GOCOVRI and ADS-5102, the regulatory and competitive environment and Adamas' business in general, see Adamas’ Current Report on Form 8-K filed with the
1 Parkinson's patients with dyskinesia switched from immediate release amantadine to open-label ADS-5102 Movement Disorders Clinical Practice https://goo.gl/WKqPbA
Kim Kraemer415-939-9033 firstname.lastname@example.org Investors: Ashleigh BarretoDirector, Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc.510-450-3567 email@example.com
Source: Adamas Pharmaceuticals, Inc.